Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
myelofibrosis
Biotech
Incyte scraps cancer-related anemia program after ph. 1/2 fail
Incyte is dropping a cancer-related anemia program after its investigational small molecule failed to improve symptoms in a phase 1/2 trial.
Darren Incorvaia
Dec 13, 2024 2:30pm
Takeda pays Keros $200M upfront for rival to BMS' Reblozyl
Dec 3, 2024 7:30am
Novartis' $2.9B MorphoSys bet stumbles as safety delays filing
Oct 29, 2024 6:16am
Galecto posts myelofibrosis data as search for savior continues
Dec 22, 2023 6:50am
MorphoSys fails secondary in blood cancer trial, sinking stock
Nov 21, 2023 5:52am
FDA delays approval decision on GSK's $1.9B blood cancer bet
Jun 16, 2023 6:50am
